Zoledronic acid infusion after hip fracture decreases new fracture rate and mortality
Metadata[+] Show full item record
Osteoporosis is estimated to contribute to more than 2 million fractures each year, and about 25% of people who sustain osteoporosis-related fractures will die within a year of the fracture. After a fracture, treatment of osteoporosis with a bisphosphonate can reduce the risk of a subsequent fracture, but compliance with oral bisphosphonates is low. Intravenous (IV) bisphosphonates are a relatively new treatment option for osteoporosis. Zoledronic acid (Reclast) and ibandronate (Boniva IV) are the only IV bisphosphonates currently indicated for the treatment of osteoporosis.
Evidence-based practice 12, no. 07 (2009): 01-02